ETNB Insider Transactions
| Transaction Date (SEC Report) |
Reporting Name | Relationship | Shrs. Owned | Type | Acq./Disp. | Shrs. Transacted | Price() | Amount() |
|---|---|---|---|---|---|---|---|---|
| 2023-09-09 | Mansbach Harry H | officer: Chief Medical Officer | 100,162 | F-InKind | D | 3,821 | 16.61 | 63,467.00 |
| 2023-09-09 | Martins Ryan | officer: Chief Financial Officer | 54,221 | F-InKind | D | 2,074 | 16.61 | 34,449.00 |
| 2023-09-09 | Le-Nguyen Quoc | officer: See Remarks | 163,874 | F-InKind | D | 4,958 | 16.61 | 82,352.00 |
| 2023-08-01 | Mansbach Harry H | officer: Chief Medical Officer | 104,997 | F-InKind | D | 577 | 15.64 | 9,024.00 |
| 2023-08-17 | Mansbach Harry H | officer: Chief Medical Officer | 103,983 | F-InKind | D | 1,014 | 15.46 | 15,676.00 |
| 2023-08-17 | PALEKAR ROHAN | director, officer: Chief Executive Officer | 300,950 | F-InKind | D | 4,501 | 15.46 | 69,585.00 |
| 2023-08-01 | Martins Ryan | officer: Chief Financial Officer | 57,048 | F-InKind | D | 346 | 15.64 | 5,411.00 |
| 2023-08-17 | Martins Ryan | officer: Chief Financial Officer | 56,295 | F-InKind | D | 753 | 15.46 | 11,641.00 |
| 2023-08-01 | Le-Nguyen Quoc | officer: See Remarks | 169,846 | F-InKind | D | 577 | 15.64 | 9,024.00 |
| 2023-08-01 | Le-Nguyen Quoc | officer: See Remarks | 168,832 | F-InKind | D | 1,014 | 15.46 | 15,676.00 |
| 2023-07-17 | LAPORTE KATHLEEN | director | 12,500 | M-Exempt | A | 12,500 | 2.64 | 33,000.00 |
| 2023-07-17 | LAPORTE KATHLEEN | director | 12,500 | M-Exempt | D | 12,500 | 2.64 | 33,000.00 |
| 2023-07-17 | LAPORTE KATHLEEN | director | 0 | S-Sale | D | 12,500 | 18.80 | 235,000.00 |
| 2023-06-30 | Mansbach Harry H | officer: Chief Medical Officer | 108,456 | A-Award | A | 8,334 | 0.00 | 0.00 |
| 2023-06-30 | Mansbach Harry H | officer: Chief Medical Officer | 105,574 | F-InKind | D | 2,882 | 18.95 | 54,614.00 |
| 2023-06-30 | Le-Nguyen Quoc | officer: See Remarks | 173,305 | A-Award | A | 8,334 | 0.00 | 0.00 |
| 2023-06-30 | Le-Nguyen Quoc | officer: See Remarks | 170,423 | F-InKind | D | 2,882 | 18.95 | 54,614.00 |
| 2023-06-30 | PALEKAR ROHAN | director, officer: Chief Executive Officer | 321,978 | A-Award | A | 33,334 | 0.00 | 0.00 |
| 2023-06-30 | PALEKAR ROHAN | director, officer: Chief Executive Officer | 305,451 | F-InKind | D | 16,527 | 18.95 | 313,187.00 |
| 2023-06-30 | Martins Ryan | officer: Chief Financial Officer | 59,412 | A-Award | A | 5,834 | 0.00 | 0.00 |
| 2023-06-30 | Martins Ryan | officer: Chief Financial Officer | 57,394 | F-InKind | D | 2,018 | 18.95 | 38,241.00 |
| 2023-06-05 | PALEKAR ROHAN | director, officer: Chief Executive Officer | 301,978 | M-Exempt | A | 15,000 | 1.93 | 28,950.00 |
| 2023-06-05 | PALEKAR ROHAN | director, officer: Chief Executive Officer | 286,978 | S-Sale | D | 15,000 | 20.00 | 300,000.00 |
| 2023-06-05 | PALEKAR ROHAN | director, officer: Chief Executive Officer | 195,231 | M-Exempt | D | 15,000 | 1.93 | 28,950.00 |
| 2023-06-01 | Atkinson Edward Morrow III | director | 6,250 | M-Exempt | A | 6,250 | 2.61 | 16,312.00 |
| 2023-06-01 | Atkinson Edward Morrow III | director | 0 | S-Sale | D | 6,250 | 17.91 | 111,938.00 |
| 2023-06-01 | Atkinson Edward Morrow III | director | 0 | M-Exempt | D | 6,250 | 2.61 | 16,312.00 |
| 2023-05-09 | Le-Nguyen Quoc | officer: See Remarks | 178,654 | M-Exempt | A | 18,626 | 3.11 | 57,927.00 |
| 2023-05-09 | Le-Nguyen Quoc | officer: See Remarks | 164,971 | S-Sale | D | 13,683 | 18.11 | 247,799.00 |
| 2023-05-09 | Le-Nguyen Quoc | officer: See Remarks | 160,028 | M-Exempt | A | 60,945 | 3.11 | 189,539.00 |
| 2023-05-09 | Le-Nguyen Quoc | officer: See Remarks | 4,063 | M-Exempt | D | 60,945 | 3.11 | 189,539.00 |
| 2023-05-09 | Le-Nguyen Quoc | officer: See Remarks | 3,312 | M-Exempt | D | 18,626 | 3.11 | 57,927.00 |
| 2023-04-04 | Martins Ryan | officer: Chief Financial Officer | 53,578 | S-Sale | D | 8,721 | 14.95 | 130,379.00 |
| 2023-03-31 | Martins Ryan | officer: Chief Financial Officer | 64,893 | A-Award | A | 7,500 | 0.00 | 0.00 |
| 2023-03-31 | Martins Ryan | officer: Chief Financial Officer | 62,299 | F-InKind | D | 2,594 | 15.23 | 39,507.00 |
| 2023-03-31 | Martins Ryan | officer: Chief Financial Officer | 59,411 | A-Award | A | 5,833 | 0.00 | 0.00 |
| 2023-03-31 | Martins Ryan | officer: Chief Financial Officer | 57,393 | F-InKind | D | 2,018 | 15.23 | 30,734.00 |
| 2023-03-31 | PALEKAR ROHAN | director, officer: Chief Executive Officer | 302,413 | A-Award | A | 33,333 | 0.00 | 0.00 |
| 2023-03-31 | PALEKAR ROHAN | director, officer: Chief Executive Officer | 286,970 | F-InKind | D | 15,443 | 15.23 | 235,197.00 |
| 2023-03-31 | Mansbach Harry H | officer: Chief Medical Officer | 103,004 | A-Award | A | 8,333 | 0.00 | 0.00 |
| 2023-03-31 | Mansbach Harry H | officer: Chief Medical Officer | 100,122 | F-InKind | D | 2,882 | 15.23 | 43,893.00 |
| 2023-03-31 | Le-Nguyen Quoc | officer: See Remarks | 100,380 | A-Award | A | 3,750 | 0.00 | 0.00 |
| 2023-03-31 | Le-Nguyen Quoc | officer: See Remarks | 99,512 | A-Award | A | 8,333 | 0.00 | 0.00 |
| 2023-03-31 | Le-Nguyen Quoc | officer: See Remarks | 99,083 | F-InKind | D | 1,297 | 15.23 | 19,753.00 |
| 2023-03-31 | Le-Nguyen Quoc | officer: See Remarks | 96,630 | F-InKind | D | 2,882 | 15.23 | 43,893.00 |
| 2023-03-24 | RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner: | 11,081,584 | P-Purchase | A | 2,461,538 | 16.25 | 39,999,992.00 |
| 2022-04-25 | Hayden Michael R | director | 103,978 | P-Purchase | A | 10,000 | 2.67 | 26,700.00 |
| 2022-04-07 | Hayden Michael R | director | 93,978 | P-Purchase | A | 10,000 | 3.48 | 34,750.00 |
| 2022-03-30 | Hayden Michael R | director | 83,978 | P-Purchase | A | 6,250 | 3.62 | 22,625.00 |
| 2023-03-28 | Hayden Michael R | director | 61,538 | P-Purchase | A | 61,538 | 16.15 | 993,839.00 |
| 2023-03-23 | Martins Ryan | officer: Chief Financial Officer | 53,578 | S-Sale | D | 5,000 | 16.11 | 80,550.00 |
| 2023-03-23 | PALEKAR ROHAN | director, officer: Chief Executive Officer | 269,080 | S-Sale | D | 15,000 | 16.00 | 240,000.00 |
| 2023-03-01 | Atkinson Edward Morrow III | director | 20,000 | M-Exempt | D | 10,000 | 4.44 | 44,400.00 |
| 2023-03-01 | Atkinson Edward Morrow III | director | 10,000 | M-Exempt | A | 10,000 | 4.44 | 44,400.00 |
| 2023-03-01 | Atkinson Edward Morrow III | director | 0 | S-Sale | D | 10,000 | 13.60 | 136,000.00 |
| 2023-02-17 | Mansbach Harry H | officer: Chief Medical Officer | 94,671 | F-InKind | D | 2,127 | 13.97 | 29,714.00 |
| 2023-02-17 | Martins Ryan | officer: Chief Financial Officer | 61,118 | F-InKind | D | 1,750 | 13.97 | 24,448.00 |
| 2023-02-21 | Martins Ryan | officer: Chief Financial Officer | 58,578 | S-Sale | D | 2,540 | 13.89 | 35,281.00 |
| 2023-02-17 | Le-Nguyen Quoc | officer: See Remarks | 91,179 | F-InKind | D | 2,140 | 13.97 | 29,896.00 |
| 2023-02-17 | PALEKAR ROHAN | director, officer: Chief Executive Officer | 284,072 | F-InKind | D | 6,279 | 13.97 | 87,718.00 |
| 2023-02-09 | Altschuler Steven | director | 27,400 | A-Award | A | 27,400 | 14.70 | 402,780.00 |
| 2023-02-09 | Martins Ryan | officer: Chief Financial Officer | 110,000 | A-Award | A | 110,000 | 14.70 | 1,617,000.00 |
| 2023-02-09 | Martins Ryan | officer: Chief Financial Officer | 62,868 | A-Award | A | 30,000 | 0.00 | 0.00 |
| 2023-02-09 | Mansbach Harry H | officer: Chief Medical Officer | 120,000 | A-Award | A | 120,000 | 14.70 | 1,764,000.00 |
| 2023-02-09 | Mansbach Harry H | officer: Chief Medical Officer | 96,798 | A-Award | A | 30,000 | 0.00 | 0.00 |
| 2023-02-09 | PALEKAR ROHAN | director, officer: Chief Executive Officer | 300,000 | A-Award | A | 300,000 | 14.70 | 4,410,000.00 |
| 2023-02-09 | PALEKAR ROHAN | director, officer: Chief Executive Officer | 290,351 | A-Award | A | 75,000 | 0.00 | 0.00 |
| 2023-02-09 | Zoth Lota S. | director | 27,400 | A-Award | A | 27,400 | 14.70 | 402,780.00 |
| 2023-02-09 | Le-Nguyen Quoc | officer: See Remarks | 120,000 | A-Award | A | 120,000 | 14.70 | 1,764,000.00 |
| 2023-02-09 | Le-Nguyen Quoc | officer: See Remarks | 93,319 | A-Award | A | 30,000 | 0.00 | 0.00 |
| 2023-02-09 | LAPORTE KATHLEEN | director | 27,400 | A-Award | A | 27,400 | 14.70 | 402,780.00 |
| 2023-02-09 | Grunberg Gregory | director, 10 percent owner: | 27,400 | A-Award | A | 27,400 | 14.70 | 402,780.00 |
| 2023-02-09 | Hayden Michael R | director | 27,400 | A-Award | A | 27,400 | 14.70 | 402,780.00 |
| 2023-02-09 | Atkinson Edward Morrow III | director | 27,400 | A-Award | A | 27,400 | 14.70 | 402,780.00 |
| 2023-02-09 | DiRocco Derek | director | 27,400 | A-Award | A | 27,400 | 14.70 | 402,780.00 |
| 2023-02-08 | Martins Ryan | officer: Chief Financial Officer | 32,868 | S-Sale | D | 1,480 | 14.41 | 21,327.00 |
| 2023-02-05 | Mansbach Harry H | officer: Chief Medical Officer | 66,798 | F-InKind | D | 1,360 | 13.24 | 18,006.00 |
| 2023-02-05 | PALEKAR ROHAN | director, officer: Chief Executive Officer | 215,351 | F-InKind | D | 4,078 | 13.24 | 53,993.00 |
| 2023-02-03 | Martins Ryan | officer: Chief Financial Officer | 81,901 | M-Exempt | D | 3,000 | 3.11 | 9,330.00 |
| 2023-02-03 | Martins Ryan | officer: Chief Financial Officer | 38,960 | S-Sale | D | 3,000 | 13.11 | 39,330.00 |
| 2023-02-03 | Martins Ryan | officer: Chief Financial Officer | 38,960 | M-Exempt | A | 3,000 | 3.11 | 9,330.00 |
| 2023-02-03 | Martins Ryan | officer: Chief Financial Officer | 35,368 | S-Sale | D | 592 | 12.70 | 7,518.00 |
| 2023-02-05 | Martins Ryan | officer: Chief Financial Officer | 34,348 | F-InKind | D | 592 | 13.24 | 7,838.00 |
| 2023-02-05 | Le-Nguyen Quoc | officer: See Remarks | 63,319 | F-InKind | D | 1,390 | 13.24 | 18,404.00 |
| 2023-02-01 | Martins Ryan | officer: Chief Financial Officer | 35,960 | F-InKind | D | 408 | 12.05 | 4,916.00 |
| 2023-02-01 | Mansbach Harry H | officer: Chief Medical Officer | 68,158 | F-InKind | D | 680 | 12.05 | 8,194.00 |
| 2023-02-01 | Le-Nguyen Quoc | officer: See Remarks | 64,709 | F-InKind | D | 695 | 12.05 | 8,375.00 |
| 2023-01-03 | Martins Ryan | officer: Chief Financial Officer | 36,368 | S-Sale | D | 5,947 | 12.51 | 74,397.00 |
| 2022-11-15 | Mansbach Harry H | officer: Chief Medical Officer | 71,951 | A-Award | A | 9,000 | 0.00 | 0.00 |
| 2022-11-15 | Mansbach Harry H | officer: Chief Medical Officer | 68,838 | F-InKind | D | 3,113 | 9.79 | 30,476.00 |
| 2022-10-18 | RA CAPITAL MANAGEMENT, L.P. | director | 8,955,410 | P-Purchase | A | 1,172,741 | 7.65 | 8,971,469.00 |
| 2022-09-28 | Le-Nguyen Quoc | officer: See Remarks | 65,833 | A-Award | A | 8,333 | 0.00 | 0.00 |
| 2022-09-28 | Le-Nguyen Quoc | officer: See Remarks | 65,404 | F-InKind | D | 1,297 | 5.79 | 7,510.00 |
| 2022-09-28 | Martins Ryan | officer: Chief Financial Officer | 44,333 | A-Award | A | 5,833 | 0.00 | 0.00 |
| 2022-09-28 | Martins Ryan | officer: Chief Financial Officer | 42,315 | F-InKind | D | 2,018 | 5.76 | 11,624.00 |
| 2022-09-28 | Mansbach Harry H | officer: Chief Medical Officer | 65,833 | A-Award | A | 8,333 | 0.00 | 0.00 |
| 2022-09-28 | Mansbach Harry H | officer: Chief Medical Officer | 62,951 | F-InKind | D | 2,882 | 5.76 | 16,600.00 |
| 2022-09-28 | PALEKAR ROHAN | officer: Chief Executive Officer | 230,956 | A-Award | A | 33,333 | 0.00 | 0.00 |
| 2022-09-28 | PALEKAR ROHAN | officer: Chief Executive Officer | 219,429 | F-InKind | D | 11,527 | 5.76 | 66,396.00 |
| 2022-09-08 | PALEKAR ROHAN | officer: Chief Executive Officer | 197,623 | M-Exempt | A | 100,000 | 1.93 | 193,000.00 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Group doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Group or anyone involved with Discounting Cash Flows Group will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.